Northview Acquisition Stock Price, News & Analysis

NorthView Acquisition Corp. Rights (trading under the symbol NVACR) represent rights issued by NorthView Acquisition Corp., a special purpose acquisition company (SPAC) that trades its common stock under the symbol NVAC. The rights are part of the capital structure created in connection with NorthView’s initial public offering on the Nasdaq Global Market.

According to NorthView’s public disclosures, each unit sold in its initial public offering consisted of one share of common stock, one right and one-half of one redeemable warrant. The rights entitle the holder to receive one-tenth (1/10) of one share of NorthView common stock upon the consummation of an initial business combination. Once the securities comprising the units began separate trading, the rights started trading independently under the ticker NVACR.

NorthView Acquisition Corp. is described in its press releases as a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It was incorporated under the laws of the State of Delaware. The company completed its initial public offering of units on the Nasdaq Global Market, and its securities, including the rights, have been registered under the Securities Exchange Act of 1934.

In an 8-K filing, NorthView Acquisition Corporation reported that it is an emerging growth company incorporated in Delaware, with securities registered under Section 12(b) of the Exchange Act. The filing lists rights, each entitling the holder to receive one-tenth of one share of common stock, as trading under the symbol NVACR. The same filing also notes that the company’s organizational documents include a deadline by which it must consummate a business combination or cease operations and redeem or repurchase 100% of the shares of common stock issued in its initial public offering. An amendment to the company’s Certificate of Incorporation extended this business combination deadline from June 22, 2025 to August 22, 2025, as approved by stockholders via written consent.

NorthView has also announced a proposed business combination with Profusa, Inc., a digital health company based in Emeryville, California that develops tissue-integrated biosensors for real-time biochemical monitoring. Under the business combination agreement, upon closing of the transaction, NorthView is expected to be renamed “Profusa Inc.” and Profusa would become a publicly listed company. The transaction is subject to shareholder approvals, regulatory processes, and other customary closing conditions, as described in NorthView’s press releases and registration statement on Form S-4 filed with the SEC.

For holders and prospective investors, NVACR represents a contractual right tied to the completion of NorthView’s initial business combination. The value and outcome of these rights depend on whether a qualifying business combination is completed within the time frame set out in NorthView’s amended Certificate of Incorporation and the terms described in its offering and transaction documents.